Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations

Journal of Virology

Volumn 85, Issue 21, 2011, Pages 11300-11308

  Xu, Hong Tao ^a   Asahchop, Eugene L ^a   Oliveira, Maureen ^a   Quashie, Peter K ^a   Quan, Yudong ^a   Brenner, Bluma G ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EMTRICITABINE; ETRAVIRINE; GLUTAMIC ACID; ISOLEUCINE; LAMIVUDINE; LYSINE; METHIONINE; RECOMBINANT ENZYME; RNA DIRECTED DNA POLYMERASE; VALINE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLONE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR MODEL; MONONUCLEAR CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PROCESSING; STEADY STATE; VIRUS ATTACHMENT; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION, MISSENSE; NUCLEOTIDES; PROTEIN CONFORMATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80055119045     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05584-11     Document Type: Article

References (44)

1. Ambrose, Z., et al. 2009. The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs. J. Virol. 83:3826-3833.
2. Arts, E. J., et al. 1994. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J. Biol. Chem. 269:14672-14680.
3. Asahchop, E. L., et al. 2011. Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob. Agents Chemother. 55:600-607.
4. Azijn, H., et al. 2010. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob. Agents Chemother. 54:718-727.
5. Back, N. K., et al. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
6. Cheynier, R., S. Gratton, J. P. Vartanian, A. Meyerhans, and S. Wain-Hobson. 1997. G3A hypermutation does not result from polymerase chain reaction. AIDS Res. Hum. Retrovir. 13:985-986.
7. Chunduri, H., D. Rimland, V. Nurpeisov, C. S. Crumpacker, and P. L. Sharma. 2011. A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus. Virol. J. 8:33.
8. Das, K., et al. 2009. Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J. Biol. Chem. 284:35092-35100.
9. Diallo, K., M. Gotte, and M. A. Wainberg. 2003. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 47:3377-3383.
10. Fuentes, G. M., L. Rodriguez-Rodriguez, C. Palaniappan, P. J. Fay, and R. A. Bambara. 1996. Strand displacement synthesis of the long terminal repeats by HIV reverse transcriptase. J. Biol. Chem. 271:1966-1971.
11. Gao, L., et al. 2008. Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J. Biol. Chem. 283: 9196-9205.
12. Goff, S. P. 1990. Retroviral reverse transcriptase: synthesis, structure, and function. J. Acquir. Immune Defic. Syndr. 3:817-831.
13. Günther, S., et al. 1997. Naturally occurring hepatitis B virus genomes bearing the hallmarks of retroviral G→A hypermutation. Virology 235:104-108.
14. Hu, Z., and D. R. Kuritzkes. 2011. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J. Virol. 85:11309-11314.
15. Hu, Z. X., J. Li, S. Gallien, and D. R. Kuritzkes. 2011. Impact of the interactions of rilpivirine (E138K) and lamivudine/emtrictabine (M184V/I) resistance mutations on viral DNA synthesis and fitness of HIV-1. Antiviral Ther. 16(Suppl.):A20.
16. Jamburuthugoda, V. K., et al. 2008. Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J. Biol. Chem. 283:9206-9216.
17. Johnson, L. B., and L. D. Saravolatz. 2009. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor. Clin. Infect. Dis. 48:1123-1128.
18. Johnson, V. A., et al. 2010. Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18:156-163.
19. Keulen, W., N. K. Back, A. van Wijk, C. A. Boucher, and B. Berkhout. 1997. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase. J. Virol. 71:3346-3350.
20. Lansdon, E. B., et al. 2010. Visualizing the molecular interactions of a nucleotide analog, GS-9148, with HIV-1 reverse transcriptase-DNA complex. J. Mol. Biol. 397: 967-978.
21. Macarthur, R. D. 2011. Clinical trial report: TMC278 (rilpivirine) versus efavirenz as initial therapy in treatment-naive, HIV-1-infected patients. Curr. Infect. Dis. Rep. 13:1-3.
22. Martinez-Cajas, J. L., and M. A. Wainberg. 2008. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68:43-72.
23. Martinez-Picado, J., and M. A. Martinez. 2008. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 134:104-123.
24. Mocroft, A., et al. 2003. Decline in the AIDS and death rates in the Euro-SIDA study: an observational study. Lancet 362:22-29.
25. Naeger, L. K., N. A. Margot, and M. D. Miller. 2001. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir. Ther. 6:115-126.
26. Nissley, D. V., et al. 2007. Characterization of novel non-nucleoside reverse transcriptase (RT) inhibitor resistance mutations at residues 132 and 135 in the 51 kDa subunit of HIV-1 RT. Biochem. J. 404:151-157.
27. Olivares, I., et al. 1999. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol. 73:6293-6298.
28. Poveda, E., et al. 2008. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 22:2395-2398.
29. Prlic, A., et al. 2010. Pre-calculated protein structure alignments at the RCSB PDB website. Bioinformatics 26:2983-2985.
30. Quan, Y., et al. 2003. Drug resistance profiles of recombinant reverse trans-criptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res. Hum. Retrovir. 19:743-753.
31. Quan, Y., et al. 1996. Endogenous reverse transcription assays reveal highlevel resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1. J. Virol. 70:5642-5645.
32. Roy, A., A. Kucukural, and Y. Zhang. 2010. I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5:725-738.
33. Schatz, O., J. Mous, and S. F. Le Grice. 1990. HIV-1 RT-associated ribonuclease H displays both endonuclease and 3'-5' exonuclease activity. EMBO J. 9:1171-1176.
34. Torres, R. A., and M. Barr. 1997. Impact of combination therapy for HIV infection on inpatient census. N. Engl. J. Med. 336:1531-1532.
35. Trott, O., and A. J. Olson. 2010. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31:455-461.
36. Turner, D., B. Brenner, and M. A. Wainberg. 2003. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin. Diagn. Lab. Immunol. 10:979-981.
37. Turner, D., and M. A. Wainberg. 2006. HIV transmission and primary drug resistance. AIDS Rev. 8:17-23.
38. Vingerhoets, J., et al. 2010. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled phase III clinical studies. AIDS 24:503-514.
39. Wainberg, M. A. 2003. HIV resistance to nevirapine and other non-nucleoside reverse transcriptase inhibitors. J. Acquir. Immune Defic. Syndr. 34(Suppl. 1):S2-S7.
40. Wainberg, M. A. 2004. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti Infect. Ther. 2:147-151.
41. Wainberg, M. A., and G. Friedland. 1998. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977-1983.
42. Xu, H., et al. 2009. Human immunodeficiency virus type 1 recombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob. Agents Chemother. 53:4667-4672.
43. Xu, H. T., et al. 2010. Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C. Retrovirology 7:80.
44. Xu, H. T., et al. 2010. The M230L nonnucleoside reverse transcriptase inhibitor resistance mutation in HIV-1 reverse transcriptase impairs enzymatic function and viral replicative capacity. Antimicrob. Agents Chemother. 54:2401-2408.